Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells - PubMed (original) (raw)
Clinical Trial
Results of a phase I clinical trial of vaccination of glioma patients with fusions of dendritic and glioma cells
T Kikuchi et al. Cancer Immunol Immunother. 2001 Sep.
Abstract
Several reports of clinical trials of immunotherapy using dendritic cells have been published to date. In this study, we investigated the safety and clinical response of immunotherapy with fusions of dendritic and glioma cells for the treatment of patients with malignant glioma. Eight patients with malignant glioma, ranging in age from 4 to 63 years old, participated in this study. Dendritic cells were generated from peripheral blood. Cultured autologous glioma cells were established from surgical specimens in each case. Fusion cells of dendritic and glioma cells were prepared with polyethylene glycol, and the fusion efficiency ranged from 9.2 to 35.3% (mean, 21.9%). All patients received the fusion cells every three weeks for a minimum of 3, and a maximum of 7, immunizations. Fusion cells were injected intradermally, close to a cervical lymph node. The percentage of CD16- and CD56-positive cells in peripheral blood lymphocytes slightly increased after immunization in 4 out of 5 cases investigated. Peripheral blood mononuclear cells were incubated with irradiated autologous glioma or U87MG cells and supernatants were harvested. In 6 cases analyzed, the concentration of interferon-gamma in the supernatant increased after immunization. Clinical results showed that there were no serious adverse effects and two partial responses. Although the results of the phase I clinical trial of fusion cells indicated that this treatment safely induced immune responses. we were unable to establish a statistically significant treatment-associated response rate, due to the limited sample population. Therefore, further evaluation of the role of adjuvant cytokines is necessary.
Similar articles
- Vaccination of recurrent glioma patients with tumour lysate-pulsed dendritic cells elicits immune responses: results of a clinical phase I/II trial.
Yamanaka R, Abe T, Yajima N, Tsuchiya N, Homma J, Kobayashi T, Narita M, Takahashi M, Tanaka R. Yamanaka R, et al. Br J Cancer. 2003 Oct 6;89(7):1172-9. doi: 10.1038/sj.bjc.6601268. Br J Cancer. 2003. PMID: 14520441 Free PMC article. Clinical Trial. - Vaccination of glioma patients with fusions of dendritic and glioma cells and recombinant human interleukin 12.
Kikuchi T, Akasaki Y, Abe T, Fukuda T, Saotome H, Ryan JL, Kufe DW, Ohno T. Kikuchi T, et al. J Immunother. 2004 Nov-Dec;27(6):452-9. doi: 10.1097/00002371-200411000-00005. J Immunother. 2004. PMID: 15534489 Clinical Trial. - Clinical evaluation of dendritic cell vaccination for patients with recurrent glioma: results of a clinical phase I/II trial.
Yamanaka R, Homma J, Yajima N, Tsuchiya N, Sano M, Kobayashi T, Yoshida S, Abe T, Narita M, Takahashi M, Tanaka R. Yamanaka R, et al. Clin Cancer Res. 2005 Jun 1;11(11):4160-7. doi: 10.1158/1078-0432.CCR-05-0120. Clin Cancer Res. 2005. PMID: 15930352 Clinical Trial. - Evolutionary basis of a new gene- and immune-therapeutic approach for the treatment of malignant brain tumors: from mice to clinical trials for glioma patients.
Lowenstein PR, Castro MG. Lowenstein PR, et al. Clin Immunol. 2018 Apr;189:43-51. doi: 10.1016/j.clim.2017.07.006. Epub 2017 Jul 15. Clin Immunol. 2018. PMID: 28720549 Free PMC article. Review. - Dendritic-cell- and peptide-based vaccination strategies for glioma.
Yamanaka R. Yamanaka R. Neurosurg Rev. 2009 Jul;32(3):265-73; discussion 273. doi: 10.1007/s10143-009-0189-1. Epub 2009 Feb 13. Neurosurg Rev. 2009. PMID: 19214609 Review.
Cited by
- Dendritic cell vaccine of gliomas: challenges from bench to bed.
Zheng Y, Ma X, Feng S, Zhu H, Chen X, Yu X, Shu K, Zhang S. Zheng Y, et al. Front Immunol. 2023 Sep 14;14:1259562. doi: 10.3389/fimmu.2023.1259562. eCollection 2023. Front Immunol. 2023. PMID: 37781367 Free PMC article. Review. - The Evolution of Tumor Microenvironment in Gliomas and Its Implication for Target Therapy.
Hu Y, Li Z, Zhang Y, Wu Y, Liu Z, Zeng J, Hao Z, Li J, Ren J, Yao M. Hu Y, et al. Int J Biol Sci. 2023 Aug 21;19(13):4311-4326. doi: 10.7150/ijbs.83531. eCollection 2023. Int J Biol Sci. 2023. PMID: 37705736 Free PMC article. Review. - Knowledge structure and hotspots research of glioma immunotherapy: a bibliometric analysis.
Yuan Y, Su Y, Wu Y, Xue Y, Zhang Y, Zhang Y, Zheng M, Chang T, Qu Y, Zhao T. Yuan Y, et al. Front Oncol. 2023 Aug 21;13:1229905. doi: 10.3389/fonc.2023.1229905. eCollection 2023. Front Oncol. 2023. PMID: 37671057 Free PMC article. - Prognostic survival biomarkers of tumor-fused dendritic cell vaccine therapy in patients with newly diagnosed glioblastoma.
Takei J, Kamata Y, Tanaka T, Fukasawa N, Gomisawa K, Satake M, Mori R, Yamamoto Y, Suzuki T, Oda A, Murahashi M, Fukuda T, Shimoda M, Murayama Y, Akasaki Y. Takei J, et al. Cancer Immunol Immunother. 2023 Oct;72(10):3175-3189. doi: 10.1007/s00262-023-03482-8. Epub 2023 Jun 29. Cancer Immunol Immunother. 2023. PMID: 37382632 Free PMC article. - Cell-based and cell-free immunotherapies for glioblastoma: current status and future directions.
Wang M, Wang X, Jin X, Zhou J, Zhang Y, Yang Y, Liu Y, Zhang J. Wang M, et al. Front Immunol. 2023 May 25;14:1175118. doi: 10.3389/fimmu.2023.1175118. eCollection 2023. Front Immunol. 2023. PMID: 37304305 Free PMC article. Review.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Research Materials